<DOC>
	<DOCNO>NCT02390986</DOCNO>
	<brief_summary>The purpose clinical trial evaluate long term safety efficacy LON002 .</brief_summary>
	<brief_title>An Extension Study LON002 Patients With Cancer</brief_title>
	<detailed_description>This extension study LON002 patient cancer , complete London Pharma sponsor LON002 study ( parent study ) . It provide opportunity patient continue receive treatment long patient continue derive clinical benefit . Long term safety efficacy evaluate .</detailed_description>
	<criteria>1 . Written informed consent ; 2 . Has complete LondonPharma sponsor parent trial LON002 continue clinical benefit judgement investigator ; 3 . Eligible continuation LON002 treatment end parent trial , accord parent trial protocol ; 4 . Able comply protocol LON002003 ; 5 . Women child bear potential must negative pregnancy test start treatment ; 6 . Sexually active woman childbearing potential must use acceptable form contraception duration dose 30 day thereafter ; 7 . Male subject female partner childbearing potential use condom duration dose 30 day thereafter 1 . Has complete LondonPharma sponsor parent trial LON002 ; 2 . Unequivocal evidence disease progression ; 3 . Unacceptable toxicity experience parent trial ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Malignant Neoplasm</keyword>
	<keyword>Anti-cancer drug</keyword>
</DOC>